Full-Time
Posted on 10/6/2025
Global cardiopulmonary and neuromodulation devices
No salary listed
Bologna, Metropolitan City of Bologna, Italy
In Person
LivaNova focuses on cardiopulmonary and neuromodulation medical technologies, delivering devices and therapies for heart and brain conditions. Its products, used in hospitals worldwide, include implants and related treatments that aim to improve patient health while providing clinical and economic value to healthcare systems. The company differentiates itself with a diverse, integrated portfolio backed by decades of experience and a global reach, aligning clinical outcomes with economic impact. Its goal is to improve patients’ lives by delivering meaningful health benefits and helping providers achieve better value.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
London, United Kingdom
Founded
2015
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
Employee Stock Purchase Plan
Flexible Work Hours
Paid Vacation
LivaNova has received FDA premarket approval for its aura6000 System to treat adults with moderate to severe obstructive sleep apnea. The device uses proximal hypoglossal nerve stimulation for patients with an apnea-hypopnea index between 15 and 65 who cannot tolerate or have failed first-line therapies like positive airway pressure. The approval follows the OSPREY randomised controlled trial, which met its primary endpoints after six months. At 12 months, 65% of treatment patients achieved responder status, defined as at least 50% improvement from baseline and an AHI below 20. LivaNova is preparing a next-generation device for FDA submission featuring MRI compatibility, remote configuration and rechargeable battery technology lasting up to 15 years. The company plans to commercialise the advanced system next year.
LivaNova, a medical device company, held its fourth-quarter and full-year 2025 earnings call, reporting strong financial performance. The company delivered double-digit revenue growth, expanded adjusted operating margins and generated robust cash flow across its cardiopulmonary and epilepsy businesses. CEO Vladimir Makatsaria highlighted that 2025 marked the company's fifth consecutive year of double-digit earnings per share growth and third straight year of double-digit organic revenue growth. The company also made progress towards financial targets outlined at its November investor day. The earnings call included executives Vladimir Makatsaria, Chief Financial Officer Alex Shvartsburg, Chief Innovation Officer Ahmet Tezel and Vice President of Investor Relations Briana Gotlin. The company posted a complementary presentation summarising key points on its investor relations website.
LivaNova, a medical technology company, reported its third consecutive year of double-digit organic revenue growth in 2025, driven by its Essence heart-lung machine and cardiopulmonary consumables. The company has issued 2026 revenue guidance of 6% to 7% growth. LivaNova is transitioning focus towards high-margin markets including obstructive sleep apnea, with clinical trial device approval expected in the first half of 2026. The epilepsy business received a boost from a 48% Medicare reimbursement increase effective January 2026. The company strengthened its balance sheet by reducing debt from $628 million to $377 million. LivaNova expects to maintain adjusted operating margins above 20% whilst increasing R&D investment. A $400 million litigation payment is anticipated in the third quarter of 2026.
Orrum Clinical Analytics has announced a strategic partnership with LivaNova USA to integrate its CŌRE Insights analytics platform with LivaNova's Essenz Perfusion System. The collaboration will enable automatic transfer of perfusion case data from Essenz to Orrum's platform for post-operative analysis and peer benchmarking. The integration, called CoreInsights for Essenz, allows perfusion teams to access continuous data capture, clinically relevant analytics measuring adherence to hospital and national benchmarks, and actionable insights on practice patterns and performance indicators. Built within a Patient Safety Organization recognised by the US Department of Health and Human Services, the platform provides secure data visualisation and analytics across the patient care continuum. The partnership aims to support evidence-based performance improvement in cardiopulmonary bypass patient management and extracorporeal care.
LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the quarter ended March 31, 2024 and raised full-year 2024 revenue and adjusted diluted earnings per share guidance.Financial Summary and Highlights(1). First-quarter revenue of $294.9 million increased 12.0% on a reported basis and 12.4% on a constant-currency basis, as compared to the prior-year period. Excluding the impact of the Advanced Circulatory Support (ACS) segment wind down, revenue increased 13.5% on a constant-currency basis. First-quarter U.S. GAAP diluted loss per share was $0.78 and adjusted diluted earnings per share was $0.73